The audacity of Prashant Jain and the tyranny of the stock market
Eight years of pain and uneven performance later, he is back with a bang. He has defended his position, among the best fund managers, through it all
N Mahalakshmi - August 04, 2021
Every crisis is an opportunity, if you are on the right side of equities
The asset class has delivered significantly higher return than risk-free alternatives, even through wars and market crashes
Samir Arora - May 04, 2021
"I stick with the Nifty as I feel governance is still a big issue in India"
Alternative Investment Fund True Beacon's CIO on why he does not invest in mid-caps and his investing approach
N Mahalakshmi - February 18, 2021
Is it time to get off the equity gravy train?
The benchmark indices are at an all-time high despite mutual funds selling all the way
Rajesh Padmashali - January 15, 2021
Has the Nifty topped out or will it head higher?
Powered by private banks, the benchmark is trading near its all-time high
November 21, 2020
Market goes crazy over a few and ignores the ‘core’
A self-fulfilling prophecy has been playing out with quality companies attracting more inflows
N Mahalakshmi - September 30, 2020
Will we see further earnings downgrade post Q1FY21 results?
As the lockdown continues in several parts of the country, growth is barely picking up
July 16, 2020
Is there more upside in store for pharma stocks?
Over the past year, the Nifty Pharma Index has gained 23% while the Nifty has declined by 11%
June 30, 2020
Has the market discounted the fallout of COVID-19?
The Nifty lost 40% from its all-time high before rebounding but investors are divided about the pullback
April 25, 2020
Is it the right time to buy pharma stocks?
The Nifty Pharma Index is down 27% over the past year amid pricing and regulatory pressure
September 04, 2019